The incidence and patterns of BCR/ABL rearrangements in chronic myeloid leukaemia (CML) using fluorescence in situ hybridisation (FISH)

Annals of the Academy of Medicine Singapore

Volumn 34, Issue 9, 2005, Pages 533-538

  Lim, Tse Hui ^a   Tien, S L ^a   Lim, P ^a   Lim, A S T ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Chromosomes; Dual fusion probes; Philadelphia chromosome; Variant patterns

Indexed keywords

ARTICLE; CHROMOSOME 22; CHROMOSOME 22Q; CHROMOSOME 9; CHROMOSOME 9Q; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; FUSION GENE; GENE DELETION; HUMAN; KARYOTYPING; MOLECULAR PROBE; PHILADELPHIA 1 CHROMOSOME; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PROGNOSIS;

EID: 29144474496     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984;36:93-9.
2. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcripts of abl and bcr genes in chronic myelogenous leukemia. Nature 1985;315:550-4.
3. Dewald GW, Wyatt WA, Juneau AL, Carlson RO, Zinsmeister AR, Jalal SM, et al. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood 1998;91:3357-65.
4. van der Plas DC, Hermans AB, Soekarman D, Smit EM, de Klein A, Smadja N, et al. Cytogenetic and molecular analysis in Philadelphia negative CML. Blood 1989;73:1038-44.
5. Inazawa J, Nishigaki H, Takashira H, Nishimura J, Horiike S, Taniwaki M, et al Rejoining between 9q+ and Philadelphia chromosomes results in normal looking chromosomes 9 and 22 in Ph1-negative chronic myelocytic leukemia. Hum Genet 1989;83:115-8.
6. Rassool F, Martiat P, Taj A, Klisak I, Goldman J. Interstitial insertion of varying amounts of ABL containing genetic material into chromosome 22 in Ph-negative CML. Leukemia 1990;4:273-7.
7. Macera MJ, Smith LJ, Frankel E, Szabo P, Verma RS. A Philadelphia negative chronic myelogenous leukemia with the chimeric BCR/ABL gene on chromosome 9 and b3-a2 splice junction. Cancer Genet Cytogenet 1998;101:143-7.
8. Reddy KS, Grove B. A Philadelphia-negative chronic myeloid leukemia with a BCR/ABL fusion gene on chromosome 9. Cancer Genet Cytogenet 1998;107:48-50.
9. Arana-Trejo RM, Ruiz Sanchez E, Ignacio-Ibarra G, Baez de la Fuente E, Garces O, Gomez Morales E, et al. BCR/ABL p210, p190 and p230 fusion genes in 250 Mexican patients with chronic myeloid leukaemia (CML). Clin Lab Haematol 2002;24:145-50.
10. Sugimoto T, Ijima K, Hisatomi H, Murayama T, Mizuno I, Hato A, et al. Second case of CML with aberrant BCR-ABL fusion transcript (e8/a2) with insertion of an inverted ABL intron 1b sequence. Am J Hematol 2004;77:164-6.
11. Lawce H, Durum C, Unsworth N, Olson S, Magenis RE. BCR-ABL FISH: Probes, patterns and prognosis. J Assoc Genet Technol 2002;28:40-6.
12. Primo D, Tabernero MD, Rasillo A, Sayagues JM, Espinosa AB, Chillon MC, et al. Patterns of BCR/ABL rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: incidence and underlying genetic abnormalities. Leukemia 2003;17:1124-9.
13. Cohen N, Rozenfeld-Granot G, Hardan I, Brok-Simoni F, Amariglio N, Rechavi G, et al. Subgroup of patients with Philadelphia-positive chronic myelogenous leukemias characterized by a deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis. Cancer Genet Cytogenet 2001;128:114-9.
14. Reid AG, Huntly BJ, Grace C, Green AR, Nacheva EP. Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukaemia. Br J Haematol 2003;121:419-27.
15. Huntly BJ, Reid AG, Bench AJ, Campbell LJ, Telford N, Shepherd P, et al. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 2001;98:1732-8.
16. Kolomietz E, Al-Maghrabi J, Brennan S, Karaskova J, Minkin S, Lipton J, et al. Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood 2001;97:3581-8.
17. Sinclair PB, Nacheva EP, Leversha M, Telford N, Chang J, Reid A, et al. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 2000;95:738-44.
18. Huntly BJ, Bench AJ, Delabesse E, Reid AG, Li J, Scott MA, et al. Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability. Blood 2002;99:4547-53.
19. Huntly BJ, Guilhot F, Reid AG, Vassiliou G, Hennig E, Franke C, et al. Imatinib improves but may not fully reverse the poor prognosis of CML patients with derivative chromosome 9 deletions. Blood 2003;102:2205-15.
20. Hagemeijer A, Buijs A, Smit E, Janssen B, Creemers GJ, Van der Plas D, et al. Translocation of BCR to chromosome 9: a new cytogenetic variant detected by FISH in two Ph-negative, SCA-positive patients with chronic myeloid leukemia. Genes Chromosome Cancer 1993;8:237-45.
21. Nacheva E, Holloway T, Brown K, Bloxham D, Green AR. Philadelphia- negative chronic myeloid leukemia: detection by FISH of BCR-ABL fusion gene localized either to chromosome 9 or chromosome 22. Br J Haematol 1994;87:409-12.
22. Mohamed AN, Koppitch F, Varterasian M, Karanes C, Yao KL, Sarkar FH. BCR/ABL fusion located on chromosome 9 in chronic myeloid leukemia with a masked Ph chromosome. Genes Chromosome Cancer 1995;13:133-7.
23. Michalova K, Zemanova Z, Bkezinova J, Moravcova J, Oltova A, Sobotka J, et al. Location of the BCR/ABL fusion genes on both chromosomes 9q34 in Ph negative chronic myeloid leukemia. Leuk Lymphoma 2002;43:1695-700.
24. Hsu WT, Preisler H, Szego K, Sprudzs R, Gao XZ. The ABL/BCR fusion gene on chromosome 9 in Ph-negative chronic myelogenous leukemia: a case for vigilance in fluorescence in situ hybridization interpretation. Cancer Genet Cytogenet 1998;104:57-60.
25. Takahashi N, Miura I, Ohshima A, Utsumi S, Nimura T, Hashimoto K, et al. Duplication of chromosome 9 carrying a BCR/ABL chimeric gene in Philadelphia chromosome negative chronic myeloid leukemia. Cancer Genet Cytogenet 1996;89:166-9.
26. Grossman A, Silver RT, Arlin Z, Coleman M, Camposano E, Gascon P, et al. Fine mapping of chromosome 22 breakpoints within the breakpoint cluster region (bcr) implies a role for exon 3 in determining disease duration in chronic myeloid leukemia. Am J Hum Genet 1989;45:729-38.
27. Mills KI, Sproul AM, Leibowitz D, Burnett AK. Mapping of breakpoints, and relationship to BCR-ABL RNA expression, in Philadelphia-chromosome-positive chronic myeloid leukaemia patients with a breakpoint around exon14 (b3) of the BCR gene. Leukemia 1991;5:937-41.
28. Elliot SL, Taylor KM, Taylor DL, Rodwell RL, Williams BF, Shuttlewood MM, et al. Cytogenetic response to alpha interferon is predicted in early chronic phase chronic myeloid leukemia by M-bcr breakpoint location. Leukemia 1995;9:946-50.